Literature DB >> 7697371

Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase.

R Arai1, N Karasawa, M Geffard, T Nagatsu, I Nagatsu.   

Abstract

The aim of the present study is to examine whether aromatic L-amino acid decarboxylase (AADC) catalyzes the conversion of exogenous L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine in serotonin neurons of the rat dorsal raphe nucleus. First, in order to confirm the localization of AADC in central serotonin neurons, we used an immunoperoxidase method for AADC and demonstrated that the distribution of AADC-containing neurons in the dorsal raphe nucleus corresponds very closely to the previous description on the distribution of serotonin-immunoreactive neurons. Second, in the rat that received intraperitoneally L-DOPA plus a peripheral AADC inhibitor, we used a double-labeling immunofluorescence method and showed that serotonin-stained neurons of the dorsal raphe nucleus were also immunoreactive to dopamine. The present result suggests that AADC decarboxylating L-5-hydroxytryptophan to serotonin in physiological conditions is also able to catalyze the in vivo decarboxylation of exogenous L-DOPA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7697371     DOI: 10.1016/0006-8993(94)91511-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  32 in total

1.  Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Authors:  Corinne Y Ostock; Kristin B Dupre; Karen L Eskow Jaunarajs; Hannah Walters; Jessica George; David Krolewski; Paul D Walker; Christopher Bishop
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

2.  The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.

Authors:  Sukju Gil; Changhwan Park; Jeongeun Lee; Hyunchul Koh
Journal:  Cell Mol Neurobiol       Date:  2010-03-16       Impact factor: 5.046

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 4.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 5.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

6.  L-DOPA inhibits depolarization-induced [3H]GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like receptors.

Authors:  I Silva; H Cortes; E Escartín; C Rangel; L Florán; D Erlij; J Aceves; B Florán
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 7.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 8.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Targeted manipulation of serotonergic neurotransmission affects the escalation of aggression in adult male Drosophila melanogaster.

Authors:  Olga V Alekseyenko; Carol Lee; Edward A Kravitz
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.